ArticleCureus2025
Regression of a Cardiac Calcified Amorphous Tumor Under Antiplatelet Therapy in a Patient With Ischemic Stroke: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac calcified amorphous tumor (CAT) is a rare, non-neoplastic cardiac mass typically treated surgically. Spontaneous regression under antiplatelet therapy is uncommon. A 76-year-old woman presented with sudden visual loss in the left eye. Magnetic resonance (MR) imaging revealed small ischemic strokes in the left cerebellar hemisphere and right temporal lobe. Ophthalmological examination confirmed left central retinal artery occlusion. Transthoracic echocardiography (TTE) revealed mitral annulus calcification (MAC) and a mobile mass, raising suspicion for cerebral infarction due to cardiac CAT. Treatment with aspirin and heparin was initiated. On hospital day 10, brain MRI revealed a new asymptomatic infarction in the left frontal lobe, and surgical tumor resection was planned. The patient continued aspirin therapy while awaiting surgery. Follow-up TTE showed resolution of the CAT, and the patient was managed with aspirin alone. Because most CAT cases are treated surgically, reports of successful antithrombotic therapy are rare. CAT reduction or disappearance has been observed with oral aspirin, and its antiplatelet and anti-inflammatory effects may have contributed to tumor regression. Additionally, patients with MAC managed with anticoagulants are at elevated risk for calcification progression and recurrent stroke. In select patients with CAT and MAC, aspirin therapy may be considered with careful monitoring. Nonetheless, antithrombotic therapy has limitations and requires close monitoring, even after tumor regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.